Literature DB >> 3402993

Linkage analysis using multiple DNA polymorphic markers in normal families and in families with fragile X syndrome.

S N Thibodeau1, H R Dorkins, K R Faulk, R Berry, A C Smith, R Hagerman, A King, K E Davies.   

Abstract

Linkage data, using the polymorphic markers 52A (DXS51), F9, 4D-8 (DXS98), and St14 (DXS52), are presented from 14 fragile X pedigrees and from 7 normal pedigrees derived from the collection of the Centre d'Etude du Polymorphisme Humaine. A multipoint linkage analysis indicates that the most probable order of these four loci in normal families is DXS51-F9-DXS98-DXS52. Recombination frequencies (theta) corresponding to maximum LOD scores (Z) were obtained by two-point linkage analysis for a number of linkage groups, including: DXS51-F9 (Z = 5.94, theta = 0.03), F9-DXS98 (Z = 0.51, theta = 0.26), F9-DXS52 (Z = 0.84, theta = 0.27), and DXS98-DXS52 (Z = 0.32, theta = 0.20). A multipoint linkage analysis of these loci, including the fragile X locus, was also performed for the fragile X population and the data support the relative order (DSX51, F9, DXS98)-FRAXA-DXS52. Recombination frequencies and maximum LOD scores, which again were derived from two-point linkage analyses, were obtained for the linkage groups DXS51-F9 (Z = 9.96, theta = 0) and F9-DXS52 (Z = 0.07, theta = 0.45) as well as for the groups DXS51-FRAXA (Z = 2.42, theta = 0.15), F9-FRAXA (Z = 1.30, theta = 0.18), DXS98-FRAXA (Z = 0.05, theta = 0.36), and DXS52-FRAXA (Z = 2.42, theta = 0.15). The linkage data was further tested for the presence of genetic heterogeneity both within and between the fragile X and normal families for the intervals DXS51-F9, F9-DXS52, F9-FRAXA, and DXS52-FRAXA using a modification of the A test. Except for the interval F9-FRAXA (P less than 0.10) there was no evidence of genetic heterogeneity for each of the various linkage groups examined. The heterogeneity detected for the interval F9-FRAXA, however, was most likely due to one family (Fx-28) that displayed very tight linkage between these two loci.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3402993     DOI: 10.1007/bf00366240

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  36 in total

1.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

2.  Report of the Committee on Methods of Linkage Analysis and Reporting.

Authors:  P M Conneally; J H Edwards; K K Kidd; J M Lalouel; N E Morton; J Ott; R White
Journal:  Cytogenet Cell Genet       Date:  1985

Review 3.  Fragile X syndrome: a unique mutation in man.

Authors:  R L Nussbaum; D H Ledbetter
Journal:  Annu Rev Genet       Date:  1986       Impact factor: 16.830

4.  Linkage and recombination between fragile X-linked mental retardation and the factor IX gene.

Authors:  S T Warren; T W Glover; R L Davidson; P Jagadeeswaran
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

5.  The genetic linkage map of the human X chromosome.

Authors:  D Drayna; R White
Journal:  Science       Date:  1985-11-15       Impact factor: 47.728

6.  Hypothesis regarding the nature of the fragile X mutation. A reply to Winter and Pembrey.

Authors:  W T Brown; S L Sherman; C S Dobkin
Journal:  Hum Genet       Date:  1987-03       Impact factor: 4.132

7.  Further segregation analysis of the fragile X syndrome with special reference to transmitting males.

Authors:  S L Sherman; P A Jacobs; N E Morton; U Froster-Iskenius; P N Howard-Peebles; K B Nielsen; M W Partington; G R Sutherland; G Turner; M Watson
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

8.  Cognitive profiles and the spectrum of clinical manifestations in heterozygous fra (X) females.

Authors:  M B Kemper; R J Hagerman; R S Ahmad; R Mariner
Journal:  Am J Med Genet       Date:  1986 Jan-Feb

9.  Genetic linkage heterogeneity in the fragile X syndrome.

Authors:  W T Brown; A C Gross; C B Chan; E C Jenkins
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

10.  Gene organization and recombinational hotspots in the murine major histocompatibility complex.

Authors:  M Steinmetz; D Stephan; K Fischer Lindahl
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

View more
  6 in total

1.  Estimating the stability of the proposed imprinted state of the fragile-X mutation when transmitted by females.

Authors:  P J Follette; C D Laird
Journal:  Hum Genet       Date:  1992-01       Impact factor: 4.132

2.  Exclusion of calcitonin/alpha-CGRP gene defect in a family with autosomal dominant supravalvular aortic stenosis.

Authors:  G M Pastores; V V Michels; D J Schaid; D J Driscoll; R H Feldt; S N Thibodeau
Journal:  J Med Genet       Date:  1992-01       Impact factor: 6.318

3.  An intronic region within the human factor VIII gene is duplicated within Xq28 and is homologous to the polymorphic locus DXS115 (767).

Authors:  M Patterson; J Gitschier; J Bloomfield; M Bell; H Dorkins; U Froster-Iskenius; S Sommer; J Sobell; D Schaid; S Thibodeau
Journal:  Am J Hum Genet       Date:  1989-05       Impact factor: 11.025

4.  Fragile X expression and X inactivation. I. The expression of the fragile site at Xq27.3 is not suppressed on inactive X chromosomes separated from the active homologue.

Authors:  D Wöhrle; J P Fryns; P Steinbach
Journal:  Hum Genet       Date:  1990-10       Impact factor: 4.132

5.  Linkage analysis of families with fragile-X mental retardation, using a novel RFLP marker (DXS 304).

Authors:  N Dahl; P Goonewardena; H Malmgren; K H Gustavson; G Holmgren; E Seemanova; G Annerén; A Flood; U Pettersson
Journal:  Am J Hum Genet       Date:  1989-08       Impact factor: 11.025

6.  Two progenitor cells for human oogonia inferred from pedigree data and the X-inactivation imprinting model of the fragile-X syndrome.

Authors:  C D Laird; M M Lamb; J L Thorne
Journal:  Am J Hum Genet       Date:  1990-04       Impact factor: 11.025

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.